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Background: Gallbladder cancer is the most frequent malignancy of the bile duct with high aggressive and extremely
poor prognosis. The main objective of the paper was to investigate the inhibitory effects of oridonin, a diterpenoid
isolated from Rabdosia rubescens, on gallbladder cancer both in vitro and in vivo and to explore the mechanisms
underlying oridonin-induced apoptosis and cell cycle arrest.
Methods: The anti-tumor activity of oridonin on SGC996 and NOZ cells was assessed by the MTT and colony forming
assays. Cell cycle changes were detected by flow cytometric analysis. Apoptosis was detected by annexin V/PI
double-staining and Hoechst 33342 staining assays. Loss of mitochondrial membrane potential was observed by
Rhodamine 123 staining. The in vivo efficacy of oridonin was evaluated using a NOZ xenograft model in athymic
nude mice. The expression of cell cycle- and apoptosis-related proteins in vitro and in vivo was analyzed by western blot
analysis. Activation of caspases (caspase-3, -8 and -9) was measured by caspases activity assay.
Results: Oridonin induced potent growth inhibition, S-phase arrest, apoptosis, and colony-forming inhibition in SGC996
and NOZ cells in a dose-dependent manner. Intraperitoneal injection of oridonin (5, 10, or 15 mg/kg) for 3 weeks
significantly inhibited the growth of NOZ xenografts in athymic nude mice. We demonstrated that oridonin
regulated cell cycle-related proteins in response to S-phase arrest by western blot analysis. In contrast, we
observed inhibition of NF-κB nuclear translocation and an increase Bax/Bcl-2 ratio accompanied by activated
caspase-3, caspase-9 and PARP-1 cleavage after treatment with oridonin, which indicate that the mitochondrial
pathway is involved in oridonin-mediated apoptosis.
Conclusions: Oridonin possesses potent anti-gallbladder cancer activities that correlate with regulation of the
mitochondrial pathway, which is critical for apoptosis and S-phase arrest. Therefore, oridonin has potential as a
novel anti-tumor therapy for the treatment of gallbladder cancer.
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Gallbladder cancer, the most frequent malignancy of the
bile duct, is a highly aggressive, lethal neoplasm that is
associated with high mortality and extremely poor
prognosis [1,2]. Despite recent advances in diagnostic
and therapeutic approaches, the 5-year survival rate is
generally 13%–30% [3]. Because of the absence of spe-
cific symptoms and signs, it is usually detected at an
advanced stage [4]. Surgical resection is the only poten-
tially curative therapy for gallbladder cancer [5]. Moreover,
the majority of patients have frequent recurrences follo-
wing surgery and unsatisfactory results after chemotherapy
or radiotherapy [6]. Therefore, novel effective therapeutic
drugs are urgently needed for this deadly disease.
Oridonin (Figure 1A), an active diterpenoid com-
pound purified from the Chinese herb Rabdosia rubes-
cens, has been reported to have various pharmacologicalFigure 1 Oridonin inhibits the proliferation of gallbladder cancer cell
treated with various concentrations of oridonin or vehicle for 24, 48, and 7
periods. Effects of oridonin on cell proliferation were determined by the M
obtained from 3 independent experiments. *P < 0.05, **P < 0.01 vs. the conand physiological effects, such as anti-inflammatory,
anti-bacterial, and even anti-tumor effects [7]. Studies
have shown that oridonin induces apoptosis in cells
derived from a variety of cancers, including breast can-
cer, hepatocellular carcinoma, colorectal cancer, gastric
cancer, and pancreatic cancer [8-12]. However, ordonin
has very little effect on normal human cells such as
lymphoid cells and fibroblasts [13,14]. In recent years,
oridonin has attracted more attention because it stimu-
lates cell cycle arrest and apoptosis in a wide variety of
tumors both in vivo and in vitro. Numerous proteins
and pathways have been shown to regulate oridonin-
mediated apoptosis, including the cysteine-dependent
aspartate-specific proteases (caspase) family, the Bcl-2
family, the mitogen-activated protein kinase (MAPK) fam-
ily, the nuclear factor-kappaB (NF-κB), p53, and phosphoi-
nositide 3-kinase (PI3K) signal transduction pathwayss. (A) Chemical structure of oridonin. (B) SGC996 and NOZ cells were
2 h. (C) Cells were incubated with 15 μmol/L oridonin for various time
TT assay. Data are expressed as the mean ± SD (n = 5). The data were
trol group.
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affects gallbladder cancer have not been reported.
In this study, we investigated whether oridonin induced
growth inhibition, cell cycle arrest in gallbladder cancer
cells in vitro and in vivo, and we explored the possible
mechanisms of action, which could provide experimental
evidence for the potential application of oridonin as a new
natural anti-tumor medicine for gallbladder cancer.
Methods
Materials
Oridonin was purchased from Sigma-Aldrich (St. Louis, MO,
USA). For in vitro studies, oridonin was dissolved in dimethyl
sulfoxide (DMSO) to create a stock solution (0.1 mol/L),
which was stored at −20°C. To prepare working solutions,
the stock solution was further diluted with culture media to
yield the desired oridonin concentration. Control cells were
treated with an equal volume of vehicle. The DMSO concen-
tration was kept below 0.1% in cell culture and did not have
any detectable effect on cell growth or cell death.
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium
bromide (MTT), Hoechst 33342, annexin V-FITC, propi-
dium iodide (PI), and Rhodamine 123 were purchased from
Sigma Chemical Co. (St. Louis, MO, USA). Primary anti-
bodies against caspase-3, caspase-9, NF-κB, Bax, Bcl-2,
PARP-1, cytochrome c, β-actin, and secondary antibodies
(goat-anti-rabbit or goat-anti-mouse) were purchased from
Cell Signaling Technology (Danvers, MA, USA). Antibodies
against cyclin A, cyclin B1, and cyclin D1 were purchased
from Epitomics (Burlingame, CA, USA).
Cell lines and cell culture
The human gallbladder cancer cell lines SGC996 and
NOZ were purchased from the Cell Bank of Type
Culture Collection of Chinese Academy of Sciences
(Shanghai, China). SGC996 cells were cultured in Rose-
well Park Memorial Institute (RPMI) 1640 medium
(Gibco, USA). NOZ cells were cultured in William’s
medium (Gibco). The media for both cell lines were
supplemented with 10% fetal bovine serum (Gibco),
100 μg/mL streptomycin, and 100 U/mL penicillin
(Hyclone, USA) and maintained at 37°C in a humidified
atmosphere with 5% CO2.
Cell viability assay
The viability of cells treated with oridonin was measured
by the MTT assay. During the logarithmic growth phase,
cells were collected and seeded in 96-well plates at a
density of 5 × 103 cells/well and cultured. After 12 h of
incubation, the cells were treated with oridonin (0,
1.875, 3.75, 7.5, 15, and 30 μmol/L) for 24, 48, and 72 h.
After treatment, 20 μL of MTT solution (5 mg/mL) was
added to each well and the cells were then incubated at37°C for 4 h. The culture medium was then replaced
with 100 μL of DMSO. The absorbance of the solution
at 490 nm was measured with a microplate reader
(Bio-Tek, USA). The results represent the average of 5
parallel samples. The cell inhibitory rate was calculated as
follows: Inhibitory rate (%) = (A490 control – A490 sample)/
(A490 control – A490 blank) × 100%.
Colony forming assay
SGC996 and NOZ cells were plated into a 6-well culture
plate (500 cells/well) and allowed to adhere for 10 h be-
fore treatment. After adherence, cells were treated with
oridonin (0.75, 1.5, and 3 μmol/L). After 48 h, the
oridonin-containing medium was removed, and the cells
were allowed to form colonies in complete medium for
14 days. Then, the colonies were fixed with a solution of
acetic acid and methanol (1:3) for 15 min, stained with
5% Giemsa (Sigma-Aldrich) for 30 min, and counted
manually. Digital images were taken of stained single
clones observed under a microscope (Leica, Germany).
Cell cycle analysis by flow cytometry
Cells were treated with oridonin (7.5, 15, and 30 μmol/L)
for 48 h. Both floating and adherent cells were collected
and washed with cold phosphate buffered saline (PBS) and
fixed with 70% ethanol overnight at 4°C. Cells were then
treated with staining buffer (PBS containing 1 mg/mL PI
and 10 mg/mL RNase A; Sigma-Aldrich) at 37°C in the
dark for 30 min. The samples were analyzed with a flow
cytometer (BD, San Diego, CA, USA).
Annexin V/PI staining assay for apoptosis
The cells were treated with oridonin (7.5, 15, and
30 μmol/L) for 48 h. After washing twice with cold PBS,
the cells were resuspended at a density of 1 × 106 cells/
mL. Then, 100 μL of binding buffer containing 2.5 μL of
annexin V-FITC and 1 μL of 100 μg/mL PI was added to
these cells and incubated for 30 min in the dark. Finally,
the samples were analyzed by a flow cytometer (BD).
Observation of morphological changes with Hoechst
33342 staining
After treatment with oridonin (7.5, 15, and 30 μmol/L)
for 48 h, the cells were washed in PBS and fixed with
methanol:acetic acid (3:1) at room temperature for
15 min. Then, the cells were washed in PBS and stained
with 5 μg/mL Hoechst 33342 for 10 min at 37°C. Finally,
the cells were washed with PBS and observed under a
fluorescence microscope (Leica, Germany).
Detection of mitochondrial membrane potential (ΔΨm)
variation by flow cytometry
ΔΨm was analyzed by flow cytometry following Rhodamine
123 staining [17]. After treatment with oridonin (7.5, 15,
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and the cells were washed with PBS twice and then
stained in Rhodamine 123 staining solution (5 μg/mL)
at 37°C for 20–30 min. The samples were analyzed by
using a flow cytometer (BD).
Western blot analysis
The cells were incubated with oridonin (7.5, 15, 30 μmol/L)
for 48 h, and then the adherent and floating cells were har-
vested, washed twice with ice-cold PBS, and lysed in RIPA
buffer (Beyotime Institute of Biotechnology, Beijing, China)
and protease inhibitor (Roche Applied Science, Indianapo-
lis, IN, USA) at 4°C for 5 min. After centrifugation at
14,000× g for 5 min, the protein content of the supernatant
was determined by the bicinchoninic acid (BCA) assay kit
(Beyotime) according to the manufacturer’s instructions.
The protein lysates (40 μg/lane) were separated by 10%
SDS-PAGE and blotted onto nitrocellulose membranes
(Millipore, Bedford, MA, USA). Each membrane was
blocked with 5% skim milk, and then incubated with the in-
dicated primary antibodies against caspase-3, caspase-9,
NF-κB, Bax, Bcl-2, PARP-1, cytochrome c, cyclin A, cyclin
B1, cyclin D1, and β-actin overnight at 4°C. Subsequently,
the membrane was incubated with the secondary antibodies
(HRP-conjugated goat anti-rabbit or goat anti-mouse IgG)
for 1 h at room temperature and the formed immunocom-
plex was visualized by using a Gel Doc 2000 (BioRad,
USA). The mitochondrial and cytosol fractions were ex-
tracted using the mitochondria extraction kit (Beyotime).
Caspases activity assay
Cells (5 × 105/dish) were seeded in 10 cm dishes and
treated with 7.5, 15 and 30 μmol/L of oridonn for 48 h.
After different treatments, cells were collected, washed
three times with PBS and resuspended in Cell lysates
buffer (25 mM Tris –HCl, pH 7.5, 20 mM MgCl2, and
150 mM NaCl, 1% Triton X-100, 25 μg/ml leupeptin,
and 25 μg/ml aprotinin) for 15 min on ice. Lysates were
centrifuged at 16,000 × g for 15 min, the supernatants col-
lected and protein concentration determined by Bradford
Protein Assay Kit (Beyotime, China). Cellular extracts
(30 μg) were then incubated in a 96-well microtitre plate
with 20 ng Ac-DEVD-pNA, Ac-IETD-pNA and Ac-LEHD-
pNA (Beyotime) for 2 h at 37°C. Caspases activity was
measured by cleavage of the Ac-DEVD-pNA, Ac-IETD-
pNA and Ac-LEHD-pNA substrate to pNA, the absorbance
of which was measured at 405 nm. Relative caspase activity
was calculated as a ratio of emission of treated cells to
untreated cells.
Experimental animals
Male athymic nude mice (4–6 weeks old with an initial
body weight of 20 ± 2 g) were obtained from Shanghai
SLAC Laboratory Animal Co., Ltd. (Shanghai, China). Theanimals were acclimatized at a temperature of 25°C ± 2°C
and a relative humidity of 70% ± 5% under natural light/
dark conditions for 1 week with ad libitum access food
and water. All animal treatments were performed in strict
accordance with international ethical guidelines and the
National Institutes of Health Guide for the Care and Use
of Laboratory Animals. The animal experiments were ap-
proved by the Institutional Animal Care and Use Committee
of Shanghai Jiao Tong University.In vivo tumor xenograft study
NOZ cells in log-phase growth were resuspended in
serum-free culture medium (at a density of 1 × 106 cells
in 0.2 mL), and then tumor xenografts were established
by subcutaneous inoculation of these NOZ cells into
the right flank of nude mice. Twenty-four hours post-
inoculation, the mice were randomly divided into 4
groups (10 mice/group). One group was administered
vehicle (10% DMSO and 90% PBS) intraperitoneally
(IP) and the others were administered oridonin (5, 10,
and 15 mg/kg) IP in a volume of 0.2 mL every 2 days
for up to 20 days. Tumor volume was measured using
calipers and estimated according to the following for-
mula: tumor volume (mm3) = (L ×W2)/2, where L and
W represent the length and width of the tumor, re-
spectively. On day 21, the animals were sacrificed, and
the tumor tissue was removed and weighed. Xenograft
tumors in control mice and in mice treated with
15 mg/kg oridonin were harvested and cut into sec-
tions for western blot analysis.Western blot analysis of tumor tissues
Protein was routinely extracted from tumor tissues using
RIPA buffer. Protein concentration was measured using a
BCA assay kit (Beyotime). Tumor tissue extracts contai-
ning 80 μg of protein were separated by 10% SDS-PAGE,
and then the resolved proteins were transferred to nitro-
cellulose membranes. After blocking with 5% skim milk,
the membranes were incubated with individual primary
antibodies overnight at 4°C, and the bound antibodies
were detected with an HRP-conjugated goat anti-rabbit
or goat anti-mouse IgG for 1 h. The formed immuno-
complexes were visualized by using the Gel Doc 2000.Statistical analysis
All data and results were confirmed in at least 3 independ-
ent experiments. Data are expressed as the means ± SD.
Differences between 2 sample means were assessed by
Student’s t-test using SPSS v19.0 software (IBM Corpor-
ation). A P value of less 0.05 was considered statistically
significant.
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Oridonin inhibits the proliferation of gallbladder cancer cells
To investigate the effect of oridonin on the proliferation
of cells, SGC996 and NOZ cells were treated with vari-
ous concentrations of oridonin and cell proliferation was
detected by the MTT assay. Oridonin exhibited a potent
cytotoxic effect on SGC996 and NOZ cells in a time-
and dose-dependent manner (Figure 1). These 2 tumor
cell lines showed different sensitivity to oridonin. NOZ
cells were more sensitive to oridonin than SGC996 cells.
At 30 μmol/L oridonin, the growth of SGC996 and NOZ
cells was almost completely inhibited. The ability of
gallbladder cancer cells to form colonies in the pres-
ence of oridonin was assessed by the flat plate colony
forming assay (Figure 2A). The assay results showedFigure 2 Oridonin suppresses the colony forming ability of gallbladd
(0.75, 1.5, and 3 μmol/L) and were allowed to form colonies in fresh medi
of colonies (mean ± SD, n = 3) (B) on colony formation are shown. All data
control group.that oridonin induced a dose-dependent decrease in
colony formation. Moreover, statistical analysis de-
monstrated that the mean sizes of the colonies in the
control were larger than those in the oridonin-treated
group (Figure 2B). The results indicate that oridonin
may have a long-term effect on the proliferation of
gallbladder cancer cells.
Oridonin induces cell cycle arrest at S-phase in gallbladder
cancer cells
To determine whether the effects of oridonin on the prolif-
eration of gallbladder cancer cells are mediated by inhib-
ition of cell cycle progression, the cell cycle phases of
treated cells were analyzed by flow cytometry. Oridonin-
mediated changes in the cell cycle of SGC996 and NOZer cancer cells. SGC996 and NOZ cells were treated with oridonin
um for 14 days. The photomicrographic differences (A) and influence
were from 3 independent experiments. *P < 0.05, **P < 0.01 vs. the
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for 48 h, the percentage of G0/G1-phase cells dramatically
decreased (from 74.86% to 48.90% for SGC996 cells and
from 53.80% to 23.91% for NOZ cells), whereas the per-
centage of cells in S-phase dramatically increased (from
19.22% to 39.80% for SGC996 cells and from 35.76% to
74.02% for NOZ cells) compared to control cells. Higher
oridonin concentrations had additional effects on the distri-
bution of gallbladder cancer cells in the cell cycle. These re-
sults indicate that oridonin induced S-phase arrest in a
dose-dependent manner.
We also assessed the levels of the G0/G1-related pro-
tein cyclin D1, the S-related protein cyclin A, and the
G2/M-related protein cyclin B1 by western blot analysisFigure 3 Oridonin induces cell cycle arrest at S-phase and regulates the e
SGC996 and NOZ cells were treated with oridonin (7.5, 15, and 30 μmol/L
by flow cytometry. (B) Data were expressed as mean ± SD (n = 3). (C) The
by western blot analysis, and β-actin was used as a loading control. Results wer
control group.in SGC996 and NOZ cells (Figure 3C). Oridonin treat-
ment for 48 h down-regulated cyclin A and cyclin B1
and up-regulated cyclin D1, indicating that oridonin
induces S-phase arrest in these cells.
Oridonin induces apoptosis of gallbladder cancer cells
To assess the mechanism underlying oridonin-mediated
growth inhibition, oridonin-treated SGC996 and NOZ
cells were stained with annexin V-FITC and PI for flow
cytometric analysis. Externalization of phosphatidylser-
ine (PS) from the inner leaflet to the outer leaflet of the
plasma membrane is a distinct phenomenon of early
apoptosis. As annexin V possesses high affinity for PS,
apoptotic cells can easily be detected by fluorescentlyxpression of cell cycle-related proteins in gallbladder cancer cells.
) for 48 h. (A) The cell cycle phases of the treated cells were evaluated
expression levels of cyclin A, cyclin B1, and cyclin D1 were measured
e representative of 3 independent experiments. *P< 0.05, **P< 0.01 vs. the
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cells due to its ability to permeate damaged cell mem-
branes. Oridonin treatment induced a dose-dependent in-
crease in both early and late stage apoptosis of SGC996 and
NOZ cells (Figure 4A). Oridonin at a concentration of
30 μmol/L had a more significant apoptosis-inducing effect
when compared to the number of apoptotic cells in the
control group.
Apoptosis was also confirmed by examining the nu-
clear morphology by Hoechst 33342 staining. The cells
in the control group were round and homogeneously
stained, whereas oridonin-treated cells showed obvious
chromatin condensation and fragmentation (Figure 4C).
Moreover, the numbers of apoptotic nuclei containing
condensed chromatin increased significantly as the ori-
donin concentration increased. Based on these morpho-
logic changes, oridonin appeared to cause apoptosis of
gallbladder cancer cells.
It is well known that proteins in the caspase family,
Bcl-2 family, NF-κB, and PARP play critical roles in the
apoptotic process [18-21]. We assessed these apoptosis-
related proteins by western blot analysis. Treatment with
oridonin down-regulated Bcl-2, NF-κB, and up-regulated
cleaved caspase-3, caspase-9, cleaved PARP-1, mitochon-
drial Bax and cytosol cytochrome c in a dose-dependent
manner, which may be responsible, at least in part, for
the apoptotic tendency of oridonin-treated SGC996 and
NOZ cells (Figure 5A).
Oridonin regulates caspase-3, -8 and -9 activation
The process of apoptosis involves a cascade of proteo-
lytic activity, much of it carried out by caspases. To fur-
ther characterize the apoptotic pathway activated by
oridonin, we determined the kinetics of caspase activa-
tion. The activation of caspases in ordoin-treated cells
was assessed using colorigenic tetrapeptide substrates,
Ac-DEVD-pNA, AcIETD-pNA and Ac-LEHD-pNA, which
have been shown to be selective for caspase-3, -8 and
caspase-9-like enzymatic activities, respectively. Caspase-3, -8
and -9 activity induced by oridonin at 0, 7.5, 15 and
30 μmol/L after 48 h were measured using caspase-3, -8, -9
activity kit. oridonin induced the activity of both caspase-3
and -9 in SGC996 and NOZ cells in a dose-dependent man-
ner (Figure 5B). But the activity of caspase-8 had no obvious
changed which manifest that the signal pathway is indepen-
dent of caspase-8 regulation.
Oridonin induces disruption of mitochondrial integrity in
gallbladder cancer cells
To investigate mitochondrial membrane potential (ΔΨm)
changes induced by oridonin treatment, cells were stained
with Rhodamine 123 and staining was detected by flow
cytometry. The loss of the ΔΨm was reflected by a decrease
in the intensity of Rhodamine 123 fluorescent staining,which was used to detect mitochondrial membrane in-
tegrity. Compared with the control cells, oridonin
treatment increased the ratio of Rhodamine 123-
negative cells from 2.85% to 69.1% for SGC996 cells
and from 27.6% to 80.8% for NOZ cells in a dose-
dependent manner (Figure 6). These findings suggest
that oridonin could reduce mitochondrial membrane
potential and induce mitochondrial dysfunction in
gallbladder cancer cells.
Oridonin represses the growth of NOZ cells in vivo
To determine the antitumor effect of oridonin in vivo,
mice bearing NOZ cell tumors were administered orido-
nin or vehicle (10% DMSO and 90% PBS) every 2 days
for up to 20 days. The tumors removed from these ani-
mals are shown in Figure 7A and 7C, and their mean
weights and volumes are provided in Figure 7B and 7D.
There was a marked reduction in tumor volume and
tumor weight in mice treated with oridonin compared
with control mice, and this reduction was dose dependent
(Figure 7). The appearance of the tumors was in agree-
ment with the statistical analysis of tumor volume data,
which showed that oridonin treatment significantly inhib-
ited tumor growth.
To determine whether the impact of oridonin on tumor
growth inhibition was related to caspase-3, caspase-9, NF-
κB, Bax, Bcl-2, PARP-1 and cytochrome c, we evaluated the
levels of these apoptosis-related proteins in the gallbladder
tumor tissues by western blot analysis. The results showed
down-regulation of Bcl-2 and NF-κB and up-regulation of
cleaved caspase-3, caspase-9, cleaved PARP-1, mitochon-
drial Bax and cytosol cytochrome c compared to the
control group, which was in agreement with the results
of the in vitro tests (Figure 7E).
Discussion
Previous studies have shown that oridonin possesses an-
ti‑proliferative and apoptotic activities against a variety
cancer cells [22]. The results of this study demonstrated
for the first time that oridonin decreased the viability of
gallbladder cancer cell lines. The data from the MTT
assays showed that oridonin inhibited the growth of
SGC996 and NOZ cells in a time- and dose-dependent
manner (Figure 1). Both the concentration and incuba-
tion time affected the cytotoxicity of oridonin. The col-
ony forming assay showed similar results after a longer
incubation period (Figure 2). The predominant mode of
cell death in these cells was apoptosis, as determined by
annexin V-FITC/PI staining (Figure 4A), characteristic
changes in the morphology of Hoechst 33342-stained
cells (Figure 4C), and cell cycle arrest studies (Figure 3A).
Consistent with these in vitro results, treatment of NOZ
xenografts in athymic nude mice with oridonin for
3 weeks significantly decreased the growth of the
Figure 4 Oridonin induces apoptosis in gallbladder cancer cells. SGC996 and NOZ cells were treated with oridonin (7.5, 15, and 30 μmol/L)
for 48 h. (A) Oridonin-treated SGC996 and NOZ cells were stained with annexin V-FITC/PI and analyzed by flow cytometry. (B) The percentage of
apoptotic cells is presented as the mean ± SD (n = 3). (C) Changes in apoptotic nuclear morphology were observed by Hoechst 33342 staining
and visualized by fluorescent microscopy. Results shown were representative data from 3 independent experiments. *P < 0.05, **P < 0.01 vs. the
control group.
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Figure 5 Oridonin regulates the expression of apoptosis related proteins and caspases activities in gallbladder cancer cells. SGC996
and NOZ cells were treated with oridonin (7.5, 15, and 30 μmol/L) for 48 h. (A) The expression levels of NF-κB, Bax, Bcl-2, cleaved caspase-9,
caspase-3, cleaved PARP-1, cytochrome c were detected by western blot analysis, and β-actin was used as a loading control. (B) The data of
the caspases activities were expressed as mean ± SD. The results shown were representative data from 3 independent experiments. *P < 0.05,
**P < 0.01 vs. the control group.
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dence in support of the notion that oridonin has potent
apoptotic effects against gallbladder cancer in vitro and
in vivo.
It is well known that apoptosis is a programmed process
that is essential for the development of most metazoans,
and that deregulation of apoptosis is an indicator of can-
cer [23]. Generally, there are two major apoptosis path-
ways: the death-receptor-induced extrinsic pathway and
the mitochondria-apoptosome-mediated apoptotic intrin-
sic pathway [24]. Mitochondria play an important role in
regulating many cellular functions, and mitochondrial
dysfunction has been proposed to be involved in many
pathological processes [25]. In the present study, it is
worth noting that there were similar levels of annexin-V-
positive and Rhodamine 123-negative cells, which suggests
that apoptosis is closely related to or dependent on the
loss of ΔΨm (Figure 6).In the mitochondrial pathway, NF-κB, a pro-survival
transcription factor, controls the inflammatory and im-
mune response as well as other genetic programs that
are central to cell proliferation and cell survival and
decrease the sensitivity of cancer cells to apoptosis
[26]. NF-κB inhibits apoptosis by inhibiting Bcl-2
members and inhibitors of apoptosis [27]. In this study,
inhibition of NF-κB nuclear translocation together
with the down-regulation of its target Bcl-2 family
member genes suggested that activation of NF-κB
was inhibited by oridonin during tumor progression
(Figure 5A).
The prime inducers of apoptotic pathways are pro-
apoptotic and anti-apoptotic Bcl-2 family proteins and
caspases. During apoptosis, the permeability of the
mitochondrial membrane increased, leading to a loss of
membrane potential and release of cytochrome c into
the cytosol, which binds to apoptotic protease activating
Figure 6 Oridonin disrupts mitochondrial integrity in gallbladder cancer cells. SGC996 and NOZ cells were treated with oridonin (7.5, 15, and
30 μmol/L) for 48 h. (A) Rhodamine retention was measured by flow cytometry. (B) The corresponding linear diagram shows the percentages of
Rhodamine 123-negative cells and is expressed as the mean ± SD (n = 3). The results shown were representative data from 3 independent experiments.
*P < 0.05, **P < 0.01 vs. the control group.
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have been identified as anti-apoptotic proteins, which
bind to the outer membrane of the mitochondrion and
prevent the release of cytochrome c [29]. The pro-
apoptotic members of this family, Bax and Bak, are re-
sponsible for permeabilizing the membrane under stress
and promoting the release of cytochrome c from the
mitochondria [30,31]. It has been suggested that a high
Bax to Bcl-2 ratio can cause ΔΨm collapse, release of
cytochrome c, and subsequent apoptosis [32]. Our re-
sults show that oridonin significantly decreased Bcl-2
and induced the translocation of Bax to the mitochon-
dria with the release of cytochrome c into the cytosol,suggesting that mitochondria are involved in oridonin-
induced apoptosis (Figure 5A).
Caspases, a family of cysteases, play a crucial role in
apoptosis progression, morphological changes, and DNA
fragmentation [33]. Two distinct pathways of apoptosis
have been identified as mitochondria-initiated apoptosis
occurs through caspase-9; the death receptor-mediated
pathway requires caspase-8 [34]. Bcl-2 inhibits the apop-
totic process and promotes cell survival, and Bax acts
within the mitochondria to induce the release of cyto-
chrome c, leading to caspase-9 activation, and subsequent
caspase-3 activation. Caspase-3 is one of the most import-
ant executioner caspases, and it is capable of cleaving many
Figure 7 Oridonin represses the growth of NOZ cells in athymic nude mice. NOZ cells were subcutaneously injected into the right flank of
the nude mice. The mice were then administered 0.2 mL of vehicle (10% DMSO and 90% PBS) or oridonin (5, 10, and 15 mg/kg) intraperitoneally
every 2 days for up to 3 weeks. (A) Photos of 5 representative mice (n = 10) from each group were presented to show the sizes of the resulting
tumors. (B) Tumor dimensions were periodically measured using calipers. (C and D) Tumors were excised from the animals and weighed. The
data are expressed as the mean ± SD (n = 10). *P < 0.05, **P < 0.01 vs. the control group. (E) The expression of apoptosis-related proteins in tumor
tissue was also assessed by western blot analysis, and β-actin was used as a loading control. The results shown were representative data from 3
independent experiments.
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http://www.biomedcentral.com/1471-2407/14/217important cellular substrates such as PARP [35]. In our
study, oridonin treatment activated caspase-3 and caspase-
9, regulated the cleavage of PARP-1 (Figure 5A). Further-
more, ordonin raised the enzymatic activity of caspase-3
and caspase-9 significantly but not caspase-8 (Figure 5B),
which suggested involvement of mitochondrial death path-
ways in oridonin-induced apoptosis. When we investigated
the mechanisms by which oridonin manifests its effectsagainst gallbladder cancer in an animal model, the re-
sults were in agreement with those of the in vitro tests
(Figure 7E).
Progression through the various phases of the cell
cycle is a tightly regulated process involving the various
cyclins and cyclin-dependent kinases (Cdks), each of
which function at different cell cycle phases [36]. The
complex of cyclin A and Cdk2 initiates DNA synthesis
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http://www.biomedcentral.com/1471-2407/14/217and progression through S-phase [37]. As suggested by
our cell cycle analysis data, oridonin arrested SGC996
and NOZ cells at S-phase (Figure 3A), which might be
due to down-regulation of cyclin A and cyclin B1 and
up-regulation of cyclin D1 (Figure 3C).
Conclusions
In summary, our study showed that oridonin is a potent
growth inhibitor of gallbladder cancer in vitro and
in vivo. Growth inhibition was dose-dependent and was
related to S-phase arrest. Oridonin also caused a marked
increase in apoptosis, which was determined by charac-
teristic morphological changes, increased numbers of
apoptotic cells, and the loss of ΔΨm. Furthermore, in-
hibition of NF-κB nuclear translocation and an increased
Bax/Bcl-2 ratio was mediated by activated caspase-3 and
caspase-9 and PARP-1 cleavage. Taken together, these
observations indicate that the mitochondrial pathway is
involved in apoptosis induced by oridonin treatment.
Oridonin has potential as a novel anti-tumor therapeutic
strategy for the treatment of gallbladder cancer.
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